cd3+ teff cells
Cell therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2014 (NCT01163201)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Anemia, Refractory, with Excess of Blasts · Phase 1/Phase 2
- Burkitt Lymphoma · Phase 1/Phase 2
- Hematologic Neoplasms · Phase 1/Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 1/Phase 2
- Leukemia, Prolymphocytic · Phase 1/Phase 2
- Lymphoma · Phase 1/Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Mantle-Cell · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Myeloproliferative Disorders · Phase 1/Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cd3+ teff cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01163201 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2014 | University of Minnesota |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Minnesota | Academic/Hospital | 1 | 1 | 1 | 2014 |
1 organizations
Page 1 / 1